Full Text View
Tabular View
No Study Results Posted
Related Studies
Hypertension Control Based on Home Blood Pressure
This study is ongoing, but not recruiting participants.
Study NCT00198562   Information provided by Ministry of Health, Labour and Welfare, Japan
First Received: September 12, 2005   Last Updated: April 18, 2008   History of Changes

September 12, 2005
April 18, 2008
April 2000
March 2012   (final data collection date for primary outcome measure)
Combined cardiovascular events [ Time Frame: 5 years ] [ Designated as safety issue: No ]
Combined cardiovascular events
Complete list of historical versions of study NCT00198562 on ClinicalTrials.gov Archive Site
  • Total mortality [ Time Frame: 5 years ] [ Designated as safety issue: Yes ]
  • Cardiovascular mortality [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Myocardial infarction and new-onset angina [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Stroke and transient ischemic attack [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Renal failure [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Aortic and peripheral artery diseases [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Left ventricular mass and function [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Urinary albumin and renal function [ Time Frame: 5 years ] [ Designated as safety issue: No ]
  • Total mortality
  • Cardiovascular mortality
  • Myocardioal infarction and new-onset angina
  • Stroke and transient ischemic attack
  • Renal failure
  • Aortic and peripheral artery diseases
  • Left ventricular mass and function
  • Urinary albumin and renal function
 
Hypertension Control Based on Home Blood Pressure
Hypertension Control Based on Home Systolic Pressure Study (HOSP Study)

The aim of this trial is to study the effects of antihypertensive therapy based on home systolic blood pressure (BP) with different target levels using two classes of drugs.

The HOSP study is a multicenter, prospective, randomized, open, blinded endpoint study. The study subjects are 40-79 years old hypertensive patients. After a 4 weeks of baseline period, subjects are randomly assigned to (1) modest control group (morning home BP <140 mmHg) or (2) strict control group (morning home BP <130 mmHg), and to (a) amlodipine group or (b) losartan group. Additional antihypertensive drugs can be used if home BP is not controlled. Home BP is measured in the early morning and late evening. The participants will be followed up for 5 years.

The aim of this trial is to study the effects of antihypertensive therapy based on home systolic blood pressure (BP) with different target levels using two classes of drugs.

The HOSP study is a multicenter, prospective, randomized, open, blinded endpoint study. Inclusion criteria are 40-79 years old treated or untreated hypertensive patients without serious medical conditions. After a 4 weeks of baseline period, subjects are randomly assigned to (1) modest control group (target morning home BP <140 mmHg) or (2) strict control group (morning home BP <130 mmHg), and to (a) amlodipine group (2.5-5 mg od) or (b) losartan group (25-50 mg od). Additional antihypertensive drugs (diuretics, beta-blockers and alpha-blockers) can be used if home BP is not controlled. Home BP is measured in the early morning and late evening. Primary end point is combined cardiovascular events.The participants will be followed up for 5 years.

Phase IV
Interventional
Treatment, Randomized, Open Label, Active Control, Factorial Assignment, Safety/Efficacy Study
Hypertension
Drug: Amlodipine, Losartan
  • Active Comparator: target morning home blood pressure (below 130 mmHg vs 130-139 mmHg)
  • Active Comparator: antihypertensive drug (amlodipine vs losartan)
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Active, not recruiting
2600
March 2012
March 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Clinical diagnosis of hypertension

Exclusion Criteria:

  • Severe hypertension (treated with 3 or more antihypertensive drugs)
  • Unable to change antihypertensive drugs to a calcium antagonist or an angiotensin antagonist
  • Serious medical conditions
  • Women who may become to be pregnant
Both
40 Years to 79 Years
No
Contact information is only displayed when the study is recruiting subjects
Japan
 
NCT00198562
Yuhei Kawano, M.D., Ph.D., Director of Division of Hypertension and Nephrology, National Cardiovascular Center
H16-CV-001, 200400510B
Ministry of Health, Labour and Welfare
Japan Cardiovascular Research Foundation
Principal Investigator: Yuhei Kawano, M.D., Ph.D. Division of Hypertension and Nephrology, National Cardiovascular Center
Ministry of Health, Labour and Welfare, Japan
April 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP